ATE240122T1 - Verbindungen zum targeting - Google Patents
Verbindungen zum targetingInfo
- Publication number
- ATE240122T1 ATE240122T1 AT01921524T AT01921524T ATE240122T1 AT E240122 T1 ATE240122 T1 AT E240122T1 AT 01921524 T AT01921524 T AT 01921524T AT 01921524 T AT01921524 T AT 01921524T AT E240122 T1 ATE240122 T1 AT E240122T1
- Authority
- AT
- Austria
- Prior art keywords
- caspase
- compound
- cytotoxic
- constitutively active
- cytotoxic portion
- Prior art date
Links
- 230000008685 targeting Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 231100000433 cytotoxic Toxicity 0.000 abstract 5
- 230000001472 cytotoxic effect Effects 0.000 abstract 5
- 102000011727 Caspases Human genes 0.000 abstract 4
- 108010076667 Caspases Proteins 0.000 abstract 4
- 230000006907 apoptotic process Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- FOIAQXXUVRINCI-LBAQZLPGSA-N (2S)-2-amino-6-[[4-[2-[bis(carboxymethyl)amino]-3-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]propyl]phenyl]carbamothioylamino]hexanoic acid Chemical compound N[C@@H](CCCCNC(=S)Nc1ccc(CC(CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)cc1)C(O)=O FOIAQXXUVRINCI-LBAQZLPGSA-N 0.000 abstract 1
- 108090000397 Caspase 3 Proteins 0.000 abstract 1
- 102000004018 Caspase 6 Human genes 0.000 abstract 1
- 108090000425 Caspase 6 Proteins 0.000 abstract 1
- 102000004041 Caspase 7 Human genes 0.000 abstract 1
- 108090000567 Caspase 7 Proteins 0.000 abstract 1
- 102100029855 Caspase-3 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
- C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22056—Caspase-3 (3.4.22.56)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22059—Caspase-6 (3.4.22.59)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0007343A GB2360771A (en) | 2000-03-28 | 2000-03-28 | Compounds for targeting |
| PCT/GB2001/001354 WO2001072336A1 (en) | 2000-03-28 | 2001-03-28 | Compounds for targeting |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE240122T1 true ATE240122T1 (de) | 2003-05-15 |
Family
ID=9888460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01921524T ATE240122T1 (de) | 2000-03-28 | 2001-03-28 | Verbindungen zum targeting |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1267940B1 (de) |
| JP (1) | JP2003528156A (de) |
| KR (1) | KR20030022782A (de) |
| CN (1) | CN1420789A (de) |
| AT (1) | ATE240122T1 (de) |
| AU (1) | AU4850101A (de) |
| BR (1) | BR0109570A (de) |
| CA (1) | CA2402453A1 (de) |
| DE (1) | DE60100274T2 (de) |
| DK (1) | DK1267940T3 (de) |
| ES (1) | ES2202287T3 (de) |
| GB (2) | GB2360771A (de) |
| IL (1) | IL151675A0 (de) |
| MX (1) | MXPA02009376A (de) |
| NO (1) | NO20024587L (de) |
| NZ (1) | NZ521289A (de) |
| PL (1) | PL358482A1 (de) |
| PT (1) | PT1267940E (de) |
| RU (1) | RU2002128746A (de) |
| WO (1) | WO2001072336A1 (de) |
| ZA (1) | ZA200207157B (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1257296A2 (de) * | 2000-02-24 | 2002-11-20 | Genentech, Inc. | Caspase aktvierte prodrug-therapie |
| JP4959110B2 (ja) * | 2002-02-07 | 2012-06-20 | マサチューセッツ インスティテュート オブ テクノロジー | 抗病原体治療 |
| CN103124788B (zh) * | 2010-05-21 | 2016-01-13 | 梅里麦克制药股份有限公司 | 双特异性融合蛋白 |
| CN114173809A (zh) * | 2019-04-02 | 2022-03-11 | 伊缪纯有限公司 | 免疫刺激组合物及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9019553D0 (en) * | 1990-09-07 | 1990-10-24 | Unilever Plc | Specific binding agents |
| JPH09506761A (ja) * | 1990-11-09 | 1997-07-08 | ステファン ディー．ギリーズ | サイトカインの免疫複合体 |
| GB9120467D0 (en) * | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| AU5615594A (en) * | 1992-11-13 | 1994-06-08 | Cancer Research Fund Of Contra Costa | Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods |
| GB2289679B (en) * | 1993-01-15 | 1997-02-05 | Imp Cancer Res Tech | Compounds comprising a target cell-specific portion and a portion which has DNA endonucleolytic activity, and uses thereof |
| US5587459A (en) * | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
| US6428788B1 (en) * | 1995-03-15 | 2002-08-06 | Penn State University | Compositions and methods for specifically targeting tumors |
| JP2002505077A (ja) * | 1997-12-10 | 2002-02-19 | ワシントン大学 | 抗病原体システムおよびその使用方法 |
| US6379950B1 (en) * | 1998-01-09 | 2002-04-30 | Thomas Jefferson University | Recombinant, active caspases and uses thereof |
| US6645490B2 (en) * | 1998-03-02 | 2003-11-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities |
-
2000
- 2000-03-28 GB GB0007343A patent/GB2360771A/en not_active Withdrawn
-
2001
- 2001-03-28 WO PCT/GB2001/001354 patent/WO2001072336A1/en active IP Right Grant
- 2001-03-28 MX MXPA02009376A patent/MXPA02009376A/es unknown
- 2001-03-28 CN CN01807423A patent/CN1420789A/zh active Pending
- 2001-03-28 JP JP2001570297A patent/JP2003528156A/ja not_active Withdrawn
- 2001-03-28 CA CA002402453A patent/CA2402453A1/en not_active Abandoned
- 2001-03-28 PT PT01921524T patent/PT1267940E/pt unknown
- 2001-03-28 EP EP01921524A patent/EP1267940B1/de not_active Expired - Lifetime
- 2001-03-28 AU AU48501/01A patent/AU4850101A/en not_active Abandoned
- 2001-03-28 AT AT01921524T patent/ATE240122T1/de not_active IP Right Cessation
- 2001-03-28 RU RU2002128746/15A patent/RU2002128746A/ru not_active Application Discontinuation
- 2001-03-28 DK DK01921524T patent/DK1267940T3/da active
- 2001-03-28 GB GB0107725A patent/GB2360772B/en not_active Expired - Fee Related
- 2001-03-28 KR KR1020027012649A patent/KR20030022782A/ko not_active Application Discontinuation
- 2001-03-28 BR BR0109570-6A patent/BR0109570A/pt not_active IP Right Cessation
- 2001-03-28 DE DE60100274T patent/DE60100274T2/de not_active Expired - Fee Related
- 2001-03-28 NZ NZ521289A patent/NZ521289A/en unknown
- 2001-03-28 PL PL01358482A patent/PL358482A1/xx not_active Application Discontinuation
- 2001-03-28 ES ES01921524T patent/ES2202287T3/es not_active Expired - Lifetime
- 2001-03-28 IL IL15167501A patent/IL151675A0/xx unknown
-
2002
- 2002-09-05 ZA ZA200207157A patent/ZA200207157B/en unknown
- 2002-09-25 NO NO20024587A patent/NO20024587L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL358482A1 (en) | 2004-08-09 |
| NZ521289A (en) | 2004-04-30 |
| MXPA02009376A (es) | 2004-05-14 |
| KR20030022782A (ko) | 2003-03-17 |
| GB0107725D0 (en) | 2001-05-16 |
| CA2402453A1 (en) | 2001-10-04 |
| JP2003528156A (ja) | 2003-09-24 |
| AU4850101A (en) | 2001-10-08 |
| RU2002128746A (ru) | 2004-03-27 |
| EP1267940B1 (de) | 2003-05-14 |
| DE60100274D1 (de) | 2003-06-18 |
| ZA200207157B (en) | 2003-12-05 |
| GB2360771A (en) | 2001-10-03 |
| DK1267940T3 (da) | 2003-09-08 |
| GB0007343D0 (en) | 2000-05-17 |
| ES2202287T3 (es) | 2004-04-01 |
| GB2360772B (en) | 2002-05-22 |
| GB2360772A (en) | 2001-10-03 |
| DE60100274T2 (de) | 2004-04-01 |
| PT1267940E (pt) | 2003-09-30 |
| IL151675A0 (en) | 2003-04-10 |
| NO20024587L (no) | 2002-11-25 |
| NO20024587D0 (no) | 2002-09-25 |
| BR0109570A (pt) | 2003-01-28 |
| EP1267940A1 (de) | 2003-01-02 |
| WO2001072336A1 (en) | 2001-10-04 |
| CN1420789A (zh) | 2003-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Juillerat-Jeanneret et al. | Fibroblast activation protein-α in fibrogenic disorders and cancer: more than a prolyl-specific peptidase? | |
| NO20055209D0 (no) | Peptabody for cancerbehandling | |
| WO2001072962A3 (en) | Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods | |
| MXPA02011379A (es) | Ensayo de deteccion de genes para mejorar la probabilidad de una respuesta efectiva a terapia de cancer con el antagonista erbb. | |
| IL176007A0 (en) | Antibodies specific to c35 and pharmaceutical compositions containing the same | |
| HUP0203968A2 (hu) | Készítmények és eljárások prosztatarák terápiájára és diagnózisára | |
| SI1641483T1 (sl) | Fuzijski proteini | |
| HK1091731A1 (en) | Pharmaceutical use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer | |
| DE60033649D1 (de) | Verbindungen und therapeutische methoden | |
| MXPA04006517A (es) | Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores. | |
| ATE240122T1 (de) | Verbindungen zum targeting | |
| DE69700983D1 (de) | Ligandgerichtete enzyme-prodrug therapie | |
| YU63702A (sh) | Novo antitelo sa specifičnošću za rak debelog creva | |
| NO20051444L (no) | Medikament inneholdende disorazoler og derivater av disse for behandling av benigne og maligne tumorsykdommer. | |
| ATE407702T1 (de) | Liposomale einkapselung von alphastrahlern, und deren verwendung | |
| FR2813606B1 (fr) | Proteine bard1 tronquee, et ses applications diagnostiques et therapeutiques | |
| HUP0401199A2 (hu) | A humán immundeficiencia vírus (HIV) proteáz inhibitorainak alkalmazása sejtvándorlás és/vagy sejtinvázió, szöveti infiltráció és ödéma blokkolására az ehhez kapcsolódó betegségek terápiájára | |
| PT980379E (pt) | Oligonucleotidos quimericos e sua utilizacao | |
| AU2990300A (en) | Deglycosylated kringle 1-5 region fragments of plasminogen and methods of use | |
| UA34406A (uk) | Засіб для лікування розсіяного склерозу, спосіб лікування з його використанням та фармацевтична упаковка |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1267940 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |